Rockwell's Triferic OK'd, but without ESA-sparing use

Rockwell Medical revealed on 26 January it had won approval from the FDA to market Triferic (ferric pyrophosphate) as a replacement of iron to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease.